Live
- PCB appoints Azhar Ali as head of youth development
- Deepam-2 Scheme Reaches 5 Million Beneficiaries in Three Weeks, says Nadendla Manohar
- Will RG Kar tragedy impact Bengal bypoll results?
- BGT 2024:25: Josh Hazlewood picks four as Australia bundle out India for 150
- BRS rallies support for Lagacharla ‘victims’
- COP29: Scientists, artists, faith leaders call for greater commitment to delivery of climate finance
- Woman donates liver to husband, saves life
- Mechanic Rocky Review: Thrilling Action Film with Twists and Great Performances
- Ponguleti Sudhakar Reddy rubbishes Rahul Gandhi's claims on Modi and Adani
- ‘We can’t take things for granted’: Jayasuriya on balancing formats and Sri Lanka’s path to WTC final
Bangladesh makes 1st generic version of remdesivir
Bangladesh-based Beximco Pharmaceuticals has become the world's first company to produce a generic version of the antiviral drug remdesivir, originally developed by US-based Gilead Sciences, it was reported on Friday.
Dhaka: Bangladesh-based Beximco Pharmaceuticals has become the world's first company to produce a generic version of the antiviral drug remdesivir, originally developed by US-based Gilead Sciences, it was reported on Friday.
Remdesivir was originally designed as an Ebola treatment, the BBC reported. It works by attacking an enzyme that a virus needs in orderto replicate inside our cells. Beximco's production of the generic version will ensure quick supply of the drug to many countries in South Asia.
A recent clinical trial in the US showed the drug helped shorten the recovery time for people who were seriously ill. However, it did not significantly improve survival rates.
Experts have warned that the drug should not be seen as a "magic bullet" for coronavirus. But in the absence of any clear treatment for COVID-19, many countries are willing to try remdesivir, said the BBC report.
